On 27 September 2024, the Rwanda Ministry of Health announced the confirmation of Marburg virus disease in patients in health facilities in the country. As of 3 October, 36 cases of MVD have been reported, including 11 deaths (Case fatality rate: 31%). The cases are reported from seven of the 30 districts in the country (Gasabo, Gatsibo, Kamonyi, Kicukiro, Nyagatare, Nyarugenge and Rubavu districts). Among the confirmed cases, over 70% are health care workers from two health facilities in Kigali. Contact tracing is underway with 410 contacts under follow-up. The source of the infection is still under investigation.

One contact travelled to Belgium from Rwanda. WHO was made aware of this by the public health authorities in Belgium. They shared detailed information on the contact's situation, that they remained healthy, completed the 21-day monitoring period, did not present with any symptoms, and are not a risk to public health.

This is the first time MVD has been reported in Rwanda. The Government of Rwanda is coordinating the response with support from WHO and partners. The Ministry of Health of Rwanda announced several control measures including a ban on patient visits to hospitals, strengthening protocols in hospitals, and measures to limit contact with dead bodies.
Rwanda will start cinical trials of experimental vaccines and treatments for MVD in the next few weeks.

Marburg virus disease (MVD) is a rare but severe hemorrhagic fever, caused by Marburg virus (MARV). Although MVD is uncommon, MARV has the potential to cause outbreaks with significant case fatality rates (up to 88%). All recorded MVD outbreaks have originated in Africa.

Transmission: Fruit bats are the natural reservoir of MARV. The majority of MVD outbreaks have been connected to human entry into bat-infested mines and caves. Human can also get infected by direct contact with an infected animal (e.g., non-human primate).

Person-to-person transmission occur by direct contact (through broken skin or mucous membranes) with infected blood, secretions, and body fluids or by indirect contact with contaminated surfaces and materials like clothing, bedding and medical equipment MVD is not an airborne disease, and a person is not  contagious before symptoms appear. As a result, if proper infection prevention and control precautions are strictly followed, the risk of infection is regarded as minimal.

Incubation period: usually five to ten days (range 2-21 days)

Symptoms: The onset of MVD is usually abrupt, with non-specific, flu-like symptoms such as a high fever, severe headache, chills and malaise. Rapid worsening occurs within 2–5 days for more than half of patients, marked by gastrointestinal symptoms such as anorexia, abdominal discomfort, severe nausea, vomiting, and diarrhea. In severe cases, a rash may develop, along with bleeding from various body areas. 

Treatment: There are several experimental drugs and vaccines for Marburg, but none has been licensed to date.

Further information, see ECDC Factsheet Marburg Virus. CDC.